transient ischaemic attack
GSK’s Blenrep combination recommended by NICE to treat multiple myeloma
The decision means that eligible patients in England will be the first in the world to access the combination
NICE recommends Gideon Richter’s Ryeqo as first daily pill for endometriosis
Around 1,000 patients could benefit from the relugolix combination therapy every year
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment
AstraZeneca receives NICE recommendations for lung cancer drugs Tagrisso and Imfinzi
More than 49,000 people are diagnosed with lung cancer in the UK each year
NICE recommends Santhera’s Duchenne muscular dystrophy drug Agamree
Approximately 1,700 patients with the muscle-wasting disorder in England are expected to benefit from the decision
NICE recommends Immunocore’s Kimmtrak as first drug for aggressive eye cancer
More than 100 patients are expected to be eligible for the treatment every year
NICE recommends Blueprint Medicines’ Ayvakyt to treat rare blood disorder
Systemic mastocytosis affects approximately one in every 10,000 people in the UK
Pfizer’s Elrexfio recommended by NICE to treat relapsed and refractory multiple myeloma
Approximately 5,000 people are diagnosed with the disease every year in England
AstraZeneca’s Voydeya recommended by NICE to treat rare blood disorder PNH
The drug has been recommended for use alongside the company’s C5 inhibitors
Ipsen’s Iqirvo recommended by NICE to treat rare liver disease primary biliary cholangitis
The disease affects approximately 25,000 people in the UK, the majority of whom are women
Johnson & Johnson receives updated NICE recommendation for Tecvayli in multiple myeloma
Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK
ABPI highlights importance of NHS-industry partnerships in improving patient outcomes
Hospitals engaging in industry partnerships were found to be up to 2.5 times more likely to follow NICE guidelines